Arrowstreet Capital Limited Partnership purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,265 shares of the pharmaceutical company’s stock, valued at approximately $3,731,000. Several other […] - 2025-04-09 08:14:56
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $480.8 million dollar inflow -- that's a 3.4% increase week over week in - 2025-04-07 15:35:24
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks - 2025-04-07 12:38:05
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the pharmaceutical company’s stock. Bank of America‘s price objective would indicate a potential upside of 16.97% from the company’s […] - 2025-04-02 06:00:47
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks - 2025-03-28 14:31:33
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $702.0 million dollar outflow -- that's a 1.8% decrease - 2025-03-27 16:02:51
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong […] - 2025-03-20 06:04:53
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $392.2 million dollar outflow -- that's a 0.8% decrease week over - 2025-03-19 15:41:35
AlphaQuest LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 84.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 517 shares of the pharmaceutical company’s stock after selling 2,767 shares during the period. AlphaQuest LLC’s holdings in Vertex Pharmaceuticals were worth $208,000 as […] - 2025-03-17 08:02:56
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday. A number of other equities analysts have also weighed in on VRTX. HC Wainwright reiterated a “buy” rating and issued a $550.00 price target on shares of […] - 2025-03-13 06:26:55
Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $15,001 and $50,000 in Vertex Pharmaceuticals stock on February 24th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account. Representative Jefferson Shreve also recently made […] - 2025-03-12 06:04:59
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $306.8 million dollar outflow -- that's a 0.6% decrease week over - 2025-03-11 15:28:55
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market - 2025-03-11 08:25:00
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $434.3 million dollar outflow -- that's a 1.1% decrease - 2025-02-21 16:22:43
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday. VRTX has been the subject of a number of other reports. Scotiabank raised their price objective on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock […] - 2025-02-21 06:55:07
Blue Trust Inc. lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 76.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 634 shares of the pharmaceutical company’s stock after selling 2,077 shares during the period. Blue […] - 2025-02-19 09:02:04
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $324.0 million dollar outflow -- that's a 1.5% decrease we - 2025-02-13 15:47:21
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. Other equities analysts have also issued reports about the stock. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. […] - 2025-02-13 09:32:55
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the pharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 3.05% from […] - 2025-02-13 09:32:50
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the pharmaceutical company’s stock. Truist Financial’s price target suggests a potential upside of 14.74% from the company’s […] - 2025-02-13 08:42:49
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $430.00 to $433.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a sector perform rating on the pharmaceutical company’s stock. Several other research analysts have also issued reports on VRTX. Morgan Stanley upped their target price […] - 2025-02-03 07:01:06
Cantor Fitzgerald restated their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Friday,Benzinga reports. Cantor Fitzgerald currently has a $480.00 price target on the pharmaceutical company’s stock. VRTX has been the topic of a number of other reports. Wells Fargo & Company cut shares of Vertex […] - 2025-02-03 07:01:05
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the pharmaceutical company’s stock. A number of other analysts have also weighed in on VRTX. Citigroup began coverage on […] - 2025-02-03 07:01:05
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales. For perspective, Vertex’ - 2025-02-03 03:17:52
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Vertex Pharmaceuticals, Inc. (Symbol: VRTX), where a total of 13,551 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts - 2025-01-31 19:08:08
VRTX institutional holdings
The following institutional investment holdings of VRTX have been identified
Date
ETF ISIN/Name
Num Shares
Book value
Fatal error: Uncaught mysqli_sql_exception: Column 'Currency_Code' in field list is ambiguous in /var/www/liquidata/show_aggregate_holdings.php:119
Stack trace:
#0 /var/www/liquidata/show_aggregate_holdings.php(119): mysqli->query()
#1 {main}
thrown in /var/www/liquidata/show_aggregate_holdings.php on line 119